C3 and C9 deposition on platelet-monocyte complexes occurred via the alternative pathway
| Agonist . | RPMI . | EDTA-VBS/RPMI . | EGTA-VBS/RPMI . | |||
|---|---|---|---|---|---|---|
| C3-positive . | C9-positive . | C3-positive . | C9-positive . | C3-positive . | C9-positive . | |
| Unstimulated | 7 (5-8) | 5 (2-9) | 9 (8-11) | 5 (1-13) | 10 (7-12) | 4 (2-13) |
| Stx2 | 44 (10-82) | 15 (15-21) | 15 (7-27) | 7 (3-15) | 34 (10-40) | 17 (2-28) |
| O157LPS | 58 (35-81) | 31 (20-46) | 20 (16-44) | 8 (7-16) | 47 (10-53) | 21 (14-25) |
| Stx2/O157LPS | 60 (46-87) | 28 (15-40) | 22 (12-43) | 10 (8-21) | 55 (14-67) | 25 (5-31) |
| Agonist . | RPMI . | EDTA-VBS/RPMI . | EGTA-VBS/RPMI . | |||
|---|---|---|---|---|---|---|
| C3-positive . | C9-positive . | C3-positive . | C9-positive . | C3-positive . | C9-positive . | |
| Unstimulated | 7 (5-8) | 5 (2-9) | 9 (8-11) | 5 (1-13) | 10 (7-12) | 4 (2-13) |
| Stx2 | 44 (10-82) | 15 (15-21) | 15 (7-27) | 7 (3-15) | 34 (10-40) | 17 (2-28) |
| O157LPS | 58 (35-81) | 31 (20-46) | 20 (16-44) | 8 (7-16) | 47 (10-53) | 21 (14-25) |
| Stx2/O157LPS | 60 (46-87) | 28 (15-40) | 22 (12-43) | 10 (8-21) | 55 (14-67) | 25 (5-31) |
Data are expressed as the percentage of platelet-monocyte complexes positive for surface-bound C3 or C9 and are shown as the median and range (in parentheses) from 3 different experiments.